Reliability of prostate imaging reporting and data system version 2.1 for excluding clinically significant prostate cancer using a 1.5 tesla scanner

Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC urology Jg. 23; H. 1; S. 69 - 6
Hauptverfasser: Sharqawi, Abdallah, Drye, Naomi, Shugaba, Abdul, O’reilly, Alison, Kadry, Ahmed M., El-Sakka, A I
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 28.04.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
ISSN:1471-2490, 1471-2490
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting. Methods This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant. Results Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%. Conclusion Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
AbstractList Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting. This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant. Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%. Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting. This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant. Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%. Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
IntroductionMultiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting.MethodsThis was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant.ResultsOut of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%.ConclusionOur results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting. Methods This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant. Results Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%. Conclusion Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies. Keywords: Clinically significant prostate cancer, Multiparametric magnetic resonance imaging, PI-RADS score, Trans perineal prostate biopsy
Abstract Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting. Methods This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant. Results Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%. Conclusion Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting. Methods This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant. Results Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%. Conclusion Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting.INTRODUCTIONMultiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate cancer (PCa). It effectively identifies patients who require prostate biopsies due to the risk of clinically significant PCa. It helps patients with clinically insignificant PCa avoid the invasive biopsies and possible accompanying complications. Large clinical trials have investigated the accuracy of mpMRI in detecting PCa. We performed a local review to examine the reliability of omitting tissue sampling in men with a negative (PIRADS 2 (P2) or less) mpMRI in the primary diagnostic setting.This was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant.METHODSThis was a retrospective study of patients with clinical suspicion of PCa within a 2-year period. Patients had a mpMRI prior to having trans-perineal prostate gland biopsies. Clinically significant disease was defined as Gleason 7 and above. The descriptive data was analysed using contingency table methods. A p-value less than 0.05 was statistically significant.Out of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%.RESULTSOut of 700 patients 90 had an mpMRI score of PIRADS 2. Seventy-seven (85.5%) of these patients had a negative biopsy, 9(10%) showed Gleason 6, 4 patients showed Gleason 7 or above. 78 patients with PIRADS 2 had a PSA density of < 0.15, none of which had a clinically significant biopsy result. The negative predictive value of mpMRI from this study is 95%.Our results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.CONCLUSIONOur results are in line with negative predictive values demonstrated in the current literature. This local study, likely applicable to other district general hospitals, shows that mpMRI is a safe and reliable initial investigation to aid decisions on which patients require biopsies.
ArticleNumber 69
Audience Academic
Author Sharqawi, Abdallah
O’reilly, Alison
Shugaba, Abdul
Drye, Naomi
El-Sakka, A I
Kadry, Ahmed M.
Author_xml – sequence: 1
  givenname: Abdallah
  surname: Sharqawi
  fullname: Sharqawi, Abdallah
  email: abdallah_elmagd@yahoo.com
  organization: Urology Dept, Royal Bolton Hospital, Urology Dept, Faculty of Medicine, Suez Canal University
– sequence: 2
  givenname: Naomi
  surname: Drye
  fullname: Drye, Naomi
  organization: Urology Dept, Royal Bolton Hospital
– sequence: 3
  givenname: Abdul
  surname: Shugaba
  fullname: Shugaba, Abdul
  organization: Urology Dept, Royal Bolton Hospital
– sequence: 4
  givenname: Alison
  surname: O’reilly
  fullname: O’reilly, Alison
  organization: Urology Dept, Royal Bolton Hospital
– sequence: 5
  givenname: Ahmed M.
  surname: Kadry
  fullname: Kadry, Ahmed M.
  organization: Urology Dept, Faculty of Medicine, Suez Canal University
– sequence: 6
  givenname: A I
  surname: El-Sakka
  fullname: El-Sakka, A I
  organization: Urology Dept, Faculty of Medicine, Suez Canal University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37118694$$D View this record in MEDLINE/PubMed
BookMark eNp9ksuOFCEYhStmjHPRF3BhSNy4qRYooGBlJhMvk0xiYnRNKC4lHRpaqJrY7-EDS3WP0zPGGBbF5fsPdX7OeXMSU7RN8xLBFUKcvS0Ic0FaiLsWIkxQy540Z4j0qMVEwJMH89PmvJQ1hKjnlD1rTrt-ERDkrPn1xQavBh_8tAPJgW1OZVKTBX6jRh9HkO025WmZqWiAUZMCZVcmuwG3NhefIsArBFzKwP7UYTYLqYOPXqsQdqD4MXpXF3E6ateVthnMZS8L0IqCyZZQletJtPl589SpUOyLu-9F8-3D-69Xn9qbzx-vry5vWk2pmFrdaYGYY3igw8C5ENQMClqGNYWDY8QMzvGOUYEphNDoXguOKTbOUoLc0HUXzfVB1yS1lttcPeedTMrL_UbKo1TVuw5W9h3lwiAIGekJo5qTHgvMemsZUsaQqvXuoLWdh4012sYpq_BI9PFJ9N_lmG4lgohwIpa_eXOnkNOP2ZZJbnzRNgQVbZqLxBz2AnGKlste_4Wu05xj7VWlUG2OoJgeqVFVBz66VC_Wi6i87KuNbmlLpVb_oOowduN1TZzzdf9RwauHTu8t_glVBfAB0PXBS7buHkFQLow8JFfW5Mp9ciWrRd2hqFQ4jjYfLf2n6jegze_b
Cites_doi 10.1016/j.eururo.2011.12.058
10.1016/j.juro.2011.03.015
10.1016/j.eururo.2020.03.048
10.1148/radiol.09090475
10.1016/S0140-6736(16)32401-1
10.1016/S0033-8389(05)70150-0
10.1148/radiographics.15.4.7569131
10.1111/bju.13556
10.1016/S1076-6332(01)90095-9
10.1007/s00330-011-2377-y
10.1148/radiol.2015142818
10.1111/bju.14853
10.1007/s00330-014-3150-9
10.2214/AJR.13.11046
10.1056/NEJMoa1801993
10.1016/j.heliyon.2021.e08325
10.1148/radiol.13130801
10.1111/bju.14809
10.1007/s00330-018-5707-9
10.1016/j.eururo.2015.01.013
10.1590/s1677-5538.ibju.2015.0690
10.1016/j.eururo.2019.02.033
ContentType Journal Article
Copyright Crown 2023
2023. Crown.
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: Crown 2023
– notice: 2023. Crown.
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QP
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12894-023-01241-6
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Publicly Available Content Database



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: ProQuest Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2490
EndPage 6
ExternalDocumentID oai_doaj_org_article_73589d100647465c84729267ee61add4
PMC10148493
A747435000
37118694
10_1186_s12894_023_01241_6
Genre Journal Article
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
AFFHD
CITATION
-A0
3V.
ACRMQ
ADINQ
ALIPV
C24
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c559t-c3c916f62b5bb88995dba0e62c50bf64dbff8365925000dc7c98252dfe541fb33
IEDL.DBID RSV
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000976078400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1471-2490
IngestDate Fri Oct 03 12:32:09 EDT 2025
Tue Nov 04 02:06:50 EST 2025
Sun Nov 09 09:12:46 EST 2025
Sat Oct 11 05:43:55 EDT 2025
Tue Nov 11 10:20:16 EST 2025
Tue Nov 04 17:57:00 EST 2025
Thu Jan 02 22:52:50 EST 2025
Sat Nov 29 02:21:32 EST 2025
Sat Sep 06 07:22:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Clinically significant prostate cancer
Multiparametric magnetic resonance imaging
Trans perineal prostate biopsy
PI-RADS score
Language English
License 2023. Crown.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c559t-c3c916f62b5bb88995dba0e62c50bf64dbff8365925000dc7c98252dfe541fb33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://link.springer.com/10.1186/s12894-023-01241-6
PMID 37118694
PQID 2815599525
PQPubID 42551
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_73589d100647465c84729267ee61add4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10148493
proquest_miscellaneous_2807918514
proquest_journals_2815599525
gale_infotracmisc_A747435000
gale_infotracacademiconefile_A747435000
pubmed_primary_37118694
crossref_primary_10_1186_s12894_023_01241_6
springer_journals_10_1186_s12894_023_01241_6
PublicationCentury 2000
PublicationDate 2023-04-28
PublicationDateYYYYMMDD 2023-04-28
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-28
  day: 28
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC urology
PublicationTitleAbbrev BMC Urol
PublicationTitleAlternate BMC Urol
PublicationYear 2023
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References G Litjens (1241_CR21) 2019; 29
1241_CR30
SS Sonnad (1241_CR9) 2001; 8
RR Tourinho-Barbosa (1241_CR1) 2016; 42
AB Rosenkrantz (1241_CR13) 2020; 203
JJ Fütterer (1241_CR10) 2015; 68
N Schieda (1241_CR22) 2014; 24
FJH Drost (1241_CR16) 2019; 4
V Stefanova (1241_CR25) 2019; 201
NJ Sathianatthen (1241_CR17) 2020; 743
RD Harris (1241_CR8) 1995; 15
KK Yu (1241_CR2) 2000; 38
1241_CR19
1241_CR18
1241_CR15
B Turkbey (1241_CR7) 2010; 255
1241_CR12
M de Rooij (1241_CR14) 2014; 202
1241_CR11
1241_CR20
W Venderink (1241_CR29) 2019; 124
1241_CR3
HU Ahmed (1241_CR6) 2017; 389
1241_CR4
1241_CR28
1241_CR27
1241_CR26
V Kasivisvanathan (1241_CR5) 2018; 378
1241_CR24
1241_CR23
References_xml – ident: 1241_CR26
  doi: 10.1016/j.eururo.2011.12.058
– ident: 1241_CR24
  doi: 10.1016/j.juro.2011.03.015
– volume: 743
  start-page: 402
  year: 2020
  ident: 1241_CR17
  publication-title: Eur Urol Sept
  doi: 10.1016/j.eururo.2020.03.048
– volume: 255
  start-page: 89
  year: 2010
  ident: 1241_CR7
  publication-title: Radiology
  doi: 10.1148/radiol.09090475
– volume: 201
  start-page: 6
  year: 2019
  ident: 1241_CR25
  publication-title: Jun
– volume: 389
  start-page: 815
  year: 2017
  ident: 1241_CR6
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32401-1
– volume: 38
  start-page: 59
  year: 2000
  ident: 1241_CR2
  publication-title: Radiol Clin North Am
  doi: 10.1016/S0033-8389(05)70150-0
– volume: 203
  start-page: 749
  issue: 4
  year: 2020
  ident: 1241_CR13
  publication-title: J Urol
– volume: 15
  start-page: 813
  year: 1995
  ident: 1241_CR8
  publication-title: Radiographics
  doi: 10.1148/radiographics.15.4.7569131
– ident: 1241_CR18
  doi: 10.1111/bju.13556
– volume: 8
  start-page: 149
  year: 2001
  ident: 1241_CR9
  publication-title: Acad Radiol
  doi: 10.1016/S1076-6332(01)90095-9
– ident: 1241_CR11
  doi: 10.1007/s00330-011-2377-y
– ident: 1241_CR20
  doi: 10.1148/radiol.2015142818
– ident: 1241_CR15
– volume: 124
  start-page: 775e84
  issue: 5
  year: 2019
  ident: 1241_CR29
  publication-title: BJU Int
  doi: 10.1111/bju.14853
– volume: 24
  start-page: 1349
  year: 2014
  ident: 1241_CR22
  publication-title: Eur Radiol
  doi: 10.1007/s00330-014-3150-9
– volume: 202
  start-page: 343
  issue: 2
  year: 2014
  ident: 1241_CR14
  publication-title: AJR Am J Roentgenol
  doi: 10.2214/AJR.13.11046
– volume: 378
  start-page: 1767
  year: 2018
  ident: 1241_CR5
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1801993
– ident: 1241_CR4
  doi: 10.1016/S0140-6736(16)32401-1
– ident: 1241_CR30
  doi: 10.1016/j.heliyon.2021.e08325
– ident: 1241_CR27
– ident: 1241_CR12
  doi: 10.1148/radiol.13130801
– ident: 1241_CR23
– ident: 1241_CR3
  doi: 10.1111/bju.14809
– volume: 4
  start-page: CD012663
  year: 2019
  ident: 1241_CR16
  publication-title: Cochrane Database Syst Rev
– ident: 1241_CR28
– volume: 29
  start-page: 1600
  issue: 4
  year: 2019
  ident: 1241_CR21
  publication-title: Eur Radiol
  doi: 10.1007/s00330-018-5707-9
– volume: 68
  start-page: 1045
  year: 2015
  ident: 1241_CR10
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2015.01.013
– volume: 42
  start-page: 1081
  year: 2016
  ident: 1241_CR1
  publication-title: Int Braz J Urol
  doi: 10.1590/s1677-5538.ibju.2015.0690
– ident: 1241_CR19
  doi: 10.1016/j.eururo.2019.02.033
SSID ssj0017856
Score 2.2955651
Snippet Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection...
Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection of Prostate...
Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection...
IntroductionMultiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the detection...
Abstract Introduction Multiparametric magnetic resonance imaging (mpMRI) of the prostate gland is now the recommended initial investigation of choice for the...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 69
SubjectTerms Biopsy
Clinical significance
Clinical trials
Clinically significant prostate cancer
Family medical history
Humans
Image-Guided Biopsy - methods
Internal Medicine
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Male
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Multiparametric Magnetic Resonance Imaging
Patients
Perineum
PI-RADS score
Prostate - pathology
Prostate cancer
Prostatic Neoplasms - pathology
Reproducibility of Results
Retrospective Studies
Statistical analysis
Trans perineal prostate biopsy
Urology
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJtAQUZC4gBpY8d2nGNBVByg4gCoNyt-iZW22WofFf0f_cGdsZNtU4S4cFutvZbteXhmZ-YbQt5YsBGiEL4UUsZSWC9LraMso7SBdz7ILnVR-PmlOTrSx8ftt2utvjAnLMMD54vbb2qpW89SUaRQ0oE25S1XTQiKgWwmJNCqaUdnaogfNFqqsURGq_0VaGGEwOWYOwRvVqkmz1BC6_9TJ197lG4mTN6ImqbH6PA-uTdYkfQg7_4BuRX6h-TO1yFO_ohcYKZxRuA-p4tIT7G2A6xKOjtJXYloDhXgp673FNNEacZ0pmf5DzTK9xgFg5aG326-wQeOjkWU83OKWR-YYwRkuVrbIQMtKWbSw7KU7UkKduwcVoaRPiwfkx-Hn75__FwO_RdKB37GunS1A-MxKm6ltRocM-ltVwXFnaxsVMLbGHWNcVnsquBd41rwN7mPQQoWbV0_ITv9og_PCG1410bHQJvJSgjJtXJRuAC0ZK7tZFWQdyM5zGmG2TDJPdHKZOIZIJ5JxDOqIB-QYtuZCJGdvgDGMQPjmH8xTkHeIr0NCjIQ1XVDPQJsGCGxzAE4WmBLwskKsjuZCQLopsMjx5hBAawM1yxhuXFZkNfbYfwlJrX1YbHBOcC4YC8x2MvTzGDbI9UNnr2FET1hvcmZpyP97FeCB8fuy1q0dUHej1x6ta-_X-rz_3GpL8hdnqRMlFzvkp31chNektvubD1bLV8lGb0EDZ49eQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Publicly Available Content Database
  dbid: PIMPY
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZgi1AvvFsCBRkJiQOkmzi245xQQVQg0WoPgMrJSvyAlZZk2UdF_wc_mBkn2SVFcOK2Wnstz-bzzDgz8w0hTyvwETznNuZC-JhXVsRKeRF7UTlWWifK0EXh0_v89FSdnRWTrjx62aVV9joxKOqW7RnztkEJj21j8I35mKk0UGUx8XL-PcYeUhhr7RpqXCU7SLyVjMjO5N3J5PMmqpArIfvCGSXHS9DNSIzLMKMILFksB8YpcPj_qal_M1WX0ygvxVKDiTq--X-Fu0VudK4qPWqxdZtccfUdcv2kC8bfJT8xnbml-b6gjadzLCAB15VOv4XWR7SNR-CnsrYUc1FpSxxNz9u3dJQdphS8Zup-mNkarSjtKzVnFxRTSzCRCZ79dm2DKF1QTNeHZWl6KCg4yzNYGUZqt7hHPh6_-fD6bdw1eYgNCLmKTWbAQ_WSVaKqFNz-hK3KxElmRFJ5yW3lvcow-IutG6zJTQGXWma9Ezz1VZbtkVHd1O4-oTkrC29SUJki4VwwJY3nxnG45JqiFElEnvdPV89bLg8d7kBK6hYLGrCgAxa0jMgrBMBmJvJwhy-axRfdHWudZ0IVNg0lu1wKA7aeFUzmzskULAePyDOEj0ZtARgxZVf0ABtG3i19BLc5cFhBsogcDGbCKTfD4R45utMyS70FSkSebIbxl5g5V7tmjXOSvACnLIW97Ld43YiU5Sh7ASNqgOSBzMORevo1cJBji2fFiywiL3rQb_f19z_1wb_FeEh2WTiOPGbqgIxWi7V7RK6Z89V0uXjcHedf02ZaNg
  priority: 102
  providerName: ProQuest
Title Reliability of prostate imaging reporting and data system version 2.1 for excluding clinically significant prostate cancer using a 1.5 tesla scanner
URI https://link.springer.com/article/10.1186/s12894-023-01241-6
https://www.ncbi.nlm.nih.gov/pubmed/37118694
https://www.proquest.com/docview/2815599525
https://www.proquest.com/docview/2807918514
https://pubmed.ncbi.nlm.nih.gov/PMC10148493
https://doaj.org/article/73589d100647465c84729267ee61add4
Volume 23
WOSCitedRecordID wos000976078400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLink
  customDbUrl:
  eissn: 1471-2490
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017856
  issn: 1471-2490
  databaseCode: RSV
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3bbtMw9IhtCPHC_RIYlZGQeICMxrEd53FDm0BiVcVlKk9W4thQqaRTLxP7Dz6Yc5ykIwMe4KVqexzLxz7XnIsBnpVoI3ghqlhI6WNRVjLW2svYy9LxonKyCLconLzLRiM9meTjtihs2WW7dyHJIKkDW2v1aomSlNrYcsr_Qb0Tqy3YkdRthnz0Dyeb2EGmperKY_74XE8FhU79v8vjXxTS5WTJSxHToIiObv4fCrfgRmt4sv2GUm7DFVffgWvHbWj9Lvyg5OSmafc5m3t2SuUgaIiy6bdwkRFrogv0ragrRpmlrGkDzc6ad26M7yUMbWDmvtvZmnQi6-ouZ-eMEkUoLQlP8mJuSzS3YJR8j9OyZE8yNH1nODNCare4B5-ODj--fhO3VzbEFl2TVWxTi_amV7yUZanRl5NVWQyd4lYOS69EVXqvUwrl0kUMlc1sji4qr7yTIvFlmt6H7Xpeu4fAMl7k3iYoAOVQCMm1sl5YJ9BltXkhhxG86E7RnDadOUzwaLQyzUYb3GgTNtqoCA7ooDcjqat2-GO--GJaJjVZKnVeJaEAVyhpUXPznKvMOZWgHhARPCcyMcT7SAu2aEsYcMHURcvso2-G5idiFsFubyTyrO2DO0IzrcxYGq6T0P6NywiebsD0JOXB1W6-pjHDLEcTK8G1PGjocoNSmhHuOUJ0j2J7OPch9fRr6ChOFzZrkacRvOwI92Jdf9_UR_82_DFc54H2Rcz1LmyvFmv3BK7as9V0uRjAVjbJwqcewM7B4Wj8fhDekOCv8dvj8edBYPOfAc9JUQ
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1JbxMxFLaqFgEX9iVQwEggDjDtjGN7PAeEylI1ahLlUFB7MjMeGyKFSchSyP_gd_Abec8zkzBFcOuBWxQ7lp_zvc1-CyFPMrARHOd5wIVwAc9yESjlROBEZlmaW5H6LgofunG_r46Pk8EG-VnnwmBYZS0TvaDOxwbvyHeZinxxLCZeTb4G2DUKX1frFholLA7t8hu4bLOXnbfw_z5lbP_d0ZuDoOoqEBhYYB6YtgGTyEmWiSxT4G6IPEtDK5kRYeYkzzPnVBtfG7FXQG5ik4AXxXJnBY9chhegIPK3OIA93CRbg05vcLJ6t4iVkHVqjpK7M5D-WHqXYcwS6MpANtSf7xLwpy74TRmeDdQ881rrleD-1f_t-K6RK5W5TfdK_rhONmxxg1zsVQEFN8kPDMkuS5Uv6djRCSbBgPlNh198-yZavqngp7TIKcbT0rL4NT0tbxop24koWP7UfjejBVoCtM42HS0phsdgMBbgd722QU6bUkw5gGVptCMoGPwjWBlGCju9Rd6fy5ncJpvFuLB3CY1ZmjgTgdgXIeeCKWkcN5aDo26SVIQt8rzGj56U9Ui09-OU1CXaNKBNe7Rp2SKvEWKrmVhL3H8xnn7SlWjScVuoJI982jGXwoC9whImY2tlBNqPt8gzBKhGiQcoNGmVuAEbxtpheg88UjC6gbIW2W7MBEllmsM1NnUlKWd6DcwWebwaxl9i9F9hxwucE8YJGJYR7OVOyRErktox0p7AiGrwSoPm5kgx_OzrqGObasWTdou8qNlqva-_H-q9f5PxiFw6OOp1dbfTP7xPLjPP_DxgaptszqcL-4BcMKfz4Wz6sBIelHw8b4b7BfRQrCE
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3JbtQw1IKCKi7sS6CAkZA4QNrEsR3nWJYRiDKqWKrerNix6UjTzCgzU9H_4IN5z0mmTYED4hbFjuVnvzVvI-S5AR3Bc17FXAgfc1OJWCkvYi-MY2XlRBm6KBzs5eOxOjws9s9l8Ydo994l2eY0YJWmerkzr3xL4kruLICrYklbhrFAIINieZlc4WDJYFDX5y8Haz9CroTsU2X--N1AHIWq_b_z5nPC6WLg5AXvaRBKoxv_D85Ncr1TSOlui0G3yCVX3yabnzqX-x3yE4OW22Lep3Tm6RzTREBBpZPj0OCItl4HfCrrimLEKW3LQ9OT9l8cZdspBd2Yuh92ukJZSft8zOkpxQASDFeCGz5b2yIuNhSD8mFZmm4LCirxFFaGkdo1d8m30buvb97HXSuH2ILJsoxtZkEP9ZIZYYwCG09UpkycZFYkxkteGe9Vhi5ebNBQ2dwWYLqyyjvBU2-y7B7ZqGe1e0BozsrC2xQYo0g4F0xJ67l1HExZW5QiicjL_kb1vK3YoYOlo6RuD1rDQetw0FpG5DVe-nomVtsOL2bNd90Rr84zoYoqDYm5XAoLEp0VTObOyRTkA4_IC0QZjTwB8MKWXWoDbBira-ldsNlALQXIIrI1mAm0bIfDPdLpjpcsNFNpKAvHRESerYfxS4yPq91shXOSvADVK4W93G9xdA1SliPsBYyoAfYOYB6O1JOjUGkcGzkrXmQRedUj8dm-_n6oD_9t-lOyuf92pPc-jD8-ItdYIAMeM7VFNpbNyj0mV-3JcrJongTa_gWpD08J
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reliability+of+prostate+imaging+reporting+and+data+system+version+2.1+for+excluding+clinically+significant+prostate+cancer+using+a+1.5+tesla+scanner&rft.jtitle=BMC+urology&rft.au=Sharqawi%2C+Abdallah&rft.au=Drye%2C+Naomi&rft.au=Shugaba%2C+Abdul&rft.au=O%E2%80%99reilly%2C+Alison&rft.date=2023-04-28&rft.pub=BioMed+Central&rft.eissn=1471-2490&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12894-023-01241-6&rft.externalDocID=10_1186_s12894_023_01241_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2490&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2490&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2490&client=summon